Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens....

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

TwongStocks Apr. 28 at 12:19 PM

$LSTA Wonder how much more time they'll give Kuva to sort out the financing issues.

1 · Reply

PyraWeb Apr. 26 at 5:44 PM

$LSTA we are witnessing some very very odd price action here. After many years of negative pa, it finally popped, not nearly enough, but the boulder is rolling per se. And they want to sell at the bottom…David ‘Doesn’t release fluff’ Mazzo staying very quiet when he needs to be selling his company. No one is satisfied selling to MI2 holding(Kuva), a co once advertised as Basking Ridge based(until it was removed from the site). That tells me LSTA hasn’t put a fair effort for investors to find a reasonable offer,why? Support found on side cap lvl 3.00, bullish harami. Time for real news now or I doubt this is sustainable, being that Kuva can’t afford the buyout…they should pay 2 million to LSTA now. With that $$$, Mazzo and Buck should get off their behinds and find a decent offer in line with Wall Street price predictions. And one in line with a complete response in their study. Menditto should write investors back. It’s not a hard concept. Or it’s one nice grift for them all. 🌈🕸📐

0 · Reply

KP2021 Apr. 23 at 8:47 AM

$LSTA what do they know that we don’t?

1 · Reply

FlippinLinknz Apr. 22 at 6:11 AM

$LSTA 👀

0 · Reply

topstockalerts Apr. 21 at 4:52 PM

$LSTA new high of day 🙌

0 · Reply

prismmarketview Apr. 21 at 4:24 PM

PRISM Mid-Day Movers: Aerospace & Defense and Pharmaceuticals are Today’s Leaders. Velo3D, Inc ( NASDAQ: $VELO) ripping +33% to ~$15.59 on heavy volume after debt cut (~60%), CEO debt-to-equity move, and growing defense backlog ($9.8M contract). Sees $60–$70M 2026 rev + positive EBITDA H2. SciSparc Ltd. (NASDAQ: $SPRC) up ~23% to ~$4.23 as restructuring + pivot (MUSE IP, AI drug discovery) fuels speculative momentum in thin float. Other Notable Movers: Lisata Therapeutics ( $LSTA) up 16% Firefly Neuroscience. ( $AIFF) up 14% HUB Security ( $HUBC)down -51% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-pharmaceuticals-are-todays-leaders/

0 · Reply

prismmarketview Apr. 21 at 4:23 PM

PRISM Mid-Day Movers: Aerospace & Defense and Pharmaceuticals are Today’s Leaders. Velo3D, Inc ( NASDAQ: $VELO) ripping +33% to ~$15.59 on heavy volume after debt cut (~60%), CEO debt-to-equity move, and growing defense backlog ($9.8M contract). Sees $60–$70M 2026 rev + positive EBITDA H2. SciSparc Ltd. (NASDAQ: $SPRC) up ~23% to ~$4.23 as restructuring + pivot (MUSE IP, AI drug discovery) fuels speculative momentum in thin float. Other Notable Movers: Lisata Therapeutics ( $LSTA) up 16% Firefly Neuroscience. ( $AIFF) up 14% HUB Security (NASDAQ: $HUBC)down -51% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-pharmaceuticals-are-todays-leaders/

0 · Reply

KP2021 Apr. 21 at 4:03 PM

$LSTA looks like news incoming

1 · Reply

RichMitch Apr. 20 at 9:27 PM

$AMS $MYSE $BZAI $PHGE $LSTA Hmmm 🤔

0 · Reply

Arttard Apr. 20 at 12:02 PM

$LSTA

0 · Reply

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Jan 27, 2026, 8:00 AM EST - 3 months ago

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Jan 21, 2026, 7:00 AM EST - 3 months ago

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Nov 6, 2025, 4:30 PM EST - 6 months ago

Lisata Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 6 months ago

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Nov 4, 2025, 4:00 PM EST - 6 months ago

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Oct 20, 2025, 1:30 PM EDT - 6 months ago

Lisata Therapeutics Transcript: LD Micro Main Event XIX Investor Conference

Oct 13, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Sep 29, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Lisata Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 11 months ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the Investival Showcase USA

Mar 5, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 29, 2024, 2:00 PM EDT - 1 year ago

Lisata Therapeutics Transcript: LD Micro Main Event XVI

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q2 2024

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 2 years ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Apr 9, 2024, 10:00 AM EDT - 2 years ago

Lisata Therapeutics Transcript: LD Micro Invitational XIV 2024

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Apr 3, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Feb 29, 2024, 4:30 PM EST - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:05 PM EST - 2 years ago

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Feb 22, 2024, 8:00 AM EST - 2 years ago

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q3 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q2 2023

May 9, 2023, 4:30 PM EDT - 3 years ago

Lisata Therapeutics Earnings Call Transcript: Q1 2023

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Lisata Therapeutics Earnings Call Transcript: Q4 2022

Nov 10, 2022, 2:00 PM EST - 3 years ago

Lisata Therapeutics Earnings Call Transcript: Q3 2022

TwongStocks Apr. 28 at 12:19 PM

$LSTA Wonder how much more time they'll give Kuva to sort out the financing issues.

1 · Reply

PyraWeb Apr. 26 at 5:44 PM

0 · Reply

KP2021 Apr. 23 at 8:47 AM

$LSTA what do they know that we don’t?

1 · Reply

FlippinLinknz Apr. 22 at 6:11 AM

$LSTA 👀

0 · Reply

topstockalerts Apr. 21 at 4:52 PM

$LSTA new high of day 🙌

0 · Reply

prismmarketview Apr. 21 at 4:24 PM

0 · Reply

prismmarketview Apr. 21 at 4:23 PM

PRISM Mid-Day Movers: Aerospace & Defense and Pharmaceuticals are Today’s Leaders. Velo3D, Inc ( NASDAQ: $VELO) ripping +33% to ~$15.59 on heavy volume after debt cut (~60%), CEO debt-to-equity move, and growing defense backlog ($9.8M contract). Sees $60–$70M 2026 rev + positive EBITDA H2. SciSparc Ltd. (NASDAQ: $SPRC) up ~23% to ~$4.23 as restructuring + pivot (MUSE IP, AI drug discovery) fuels speculative momentum in thin float. Other Notable Movers: Lisata Therapeutics ( $LSTA) up 16% Firefly Neuroscience. ( $AIFF) up 14% HUB Security (NASDAQ: $HUBC)down -51% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-pharmaceuticals-are-todays-leaders/

0 · Reply

KP2021 Apr. 21 at 4:03 PM

$LSTA looks like news incoming

1 · Reply

RichMitch Apr. 20 at 9:27 PM

$AMS $MYSE $BZAI $PHGE $LSTA Hmmm 🤔

0 · Reply

Arttard Apr. 20 at 12:02 PM

$LSTA

0 · Reply

Defen Apr. 17 at 1:51 PM

$LSTA this is a real tough one Massive risk imo if deal breaks sub $2 upside if it somehow gets put back together uuugg

0 · Reply

Arttard Apr. 17 at 4:11 AM

$LSTA something is Boiling

0 · Reply

SQUEAKSBANDIT Apr. 16 at 6:50 PM

$LSTA seemed kinda crooked as CLBS back in the day serious doubt as to this buyout going through

0 · Reply

Sconniebadge Apr. 16 at 3:14 PM

$LSTA I thought that it was clearly outlined in the initial disclosures that Kuva already had the funding. This seems off.

1 · Reply

Defen Apr. 16 at 3:11 PM

$LSTA this is not good

0 · Reply

Defen Apr. 16 at 3:09 PM

$LSTA wow Not sure if I should try again. Not enough money!! How could they not know this?

0 · Reply

Tom__Brady Apr. 16 at 11:45 AM

$LSTA anyone taking a flyer that the aquisition will still go through, and buying shares down here?

2 · Reply

rade4481 Apr. 16 at 3:23 AM

$LSTA - Is this share price going back under two. I sold out at $5.00 but still took a big loss

0 · Reply

TwongStocks Apr. 15 at 8:04 PM

$LSTA 8-K filing https://www.sec.gov/ix?doc=/Archives/edgar/data/0000320017/000114036126014775/ef20070652_form8k.htm Kuva doesn;t have enough money yet to initiate the tender offer: "The Company has been informed by Parent that Parent is currently seeking alternative sources of financing on terms more favorable to Parent to fund the tender offer, and intends to launch the tender offer when its financing is finalized. The Company is in discussions with Parent regarding the financing and timing of the commencement of the tender offer. There can be no assurance as to when the tender offer will commence, if at all."

2 · Reply

Poxz82 Apr. 15 at 6:04 PM

$LSTA wtf is going on, I freaking hate this company so much now...

0 · Reply

Rolo2024 Apr. 15 at 5:02 PM

$LSTA We are worth more than a measley $5!!! Give us $5.25 and we will call it a day. 😂

0 · Reply

TwongStocks Apr. 15 at 1:48 PM

$LSTA The deadline for Kuva Labs to initiate their tender offer was extended from Apr 3 to Apr 13. It is now Apr 15 and there is complete radio silence. No SEC filings, no press releases, no tender offer yet.

1 · Reply

Market Cap	28.90M
Revenue (ttm)	170,000.00
Net Income (ttm)	-16.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,758.82%
Debt to Equity Ratio	0.00

Volume	61,700
Avg Vol	82,750
Day's Range	N/A - N/A
Shares Out	9.03M
Stochastic %K	42%
Beta	1.10
Analysts	Sell
Price Target	$9.50